<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312754</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-108</org_study_id>
    <secondary_id>Amazone</secondary_id>
    <nct_id>NCT00312754</nct_id>
  </id_info>
  <brief_title>A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome</brief_title>
  <official_title>A Phase IV, One-arm, Open-label, Multicenter Study Evaluating Effect of Treatment Change to Atazanavir/Ritonavir on Brachial Endothelial Function of HIV Infected Patient Receiving Function in HIV Infected Patient Receiving Potent Antiretroviral Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if BMS-232632 administered as
      Atazanavir/ritonavir (ATV/RTV) is superior to an anti-retroviral regimen including
      Lopinavir/ritonavir (LPV/RTV), as assessed by an increased brachial artery flow-mediated
      vasodilatation (FMD), in HIV-infected patients. The safety of this treatment will also be
      studied.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate a significant increase in brachial artery FMD after a 24-week ATV/RTV treatment period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in FMD from ref. value after a 12-wk ATV/RTV treatment period.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of pts w/ virologic rebound after a 24-wk ATV/RTV treatment period.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of pts w/ metabolic syndrome after a 24-wk ATV/RTV treament period.-</measure>
  </secondary_outcome>
  <enrollment>70</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Documented Metabolic Syndrome by at least 3 of the following parameters:

          -  Abdominal obesity, assessed by waist circumference (for men &gt;103 cm, for women &gt;88
             cm).

          -  Triglycerides &gt; 150 mg/dl.

          -  HDL cholestrol (for men &lt;40 mg/dl, for women &lt;50 mg/dl).

          -  Blood pressure &gt; or equal to 130/85 mm Hg.

          -  Fasting serum glucose &gt; or equal to 110 mg/dl.

          -  HIV RNA &lt; 50 copies/mL.

          -  IP within 3 months prior to selection.

        Exclusion Criteria:

        -Treated Metabolic Syndrom
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yacia Bennai, MD</last_name>
    <role>Study Director</role>
    <affiliation>00 33 1 58 83 63 84</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2005</study_first_submitted>
  <study_first_submitted_qc>April 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2006</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

